Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of vertigo control following common treatments in Ménière’s disease
2019-001540-22Phase 2Terminated
- Sponsor
- Department of Otorhinolaryngology, Medical University of Vienna
- Start
- Jun 2019
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of lidocaine and gentamicin in Meniere Disease (3 arms), sponsored by Department of Otorhinolaryngology, Medical University of Vienna. Primary endpoint: Vertigo control rate at 24 months. Started Jun 2019; status: terminated.
02
Drugs
lidocainegentamicin
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2019-001540-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001540-22.